Invizius Secures £950,000 for Innovative Dialysis Treatment
Invizius, a pioneering biotech company headquartered in Edinburgh, Scotland, UK, is making significant strides in its mission to develop innovative treatments for patients who rely on dialysis. Recently, the company successfully raised £950,000 in funding, which marks a notable achievement in its continued growth and development. This funding round was spearheaded by Mercia Ventures and enjoyed the backing of several esteemed investors including Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital, and Scottish Enterprise. These contributions are vital as Invizius aims to enhance the quality of care for renal patients facing rigorous treatment regimens.
Founded in 2018 as a spin-out from the prestigious University of Edinburgh, Invizius operates under the dynamic leadership of Magnus Nicolson, who serves as the CEO.
The company is focused on developing a revolutionary treatment known as H-Guard, which is designed to improve outcomes for patients undergoing continuous renal replacement therapy (CRRT). This particular type of dialysis is especially critical for individuals suffering from acute kidney injury while in intensive care units (ICUs). The funding secured will facilitate the next stage of clinical trials for H-Guard, where researchers will evaluate its effectiveness in altering immune responses and mitigating renal tubule damage during dialysis.
The H-Guard treatment addresses the severe inflammatory reactions that can commonly occur during dialysis procedures, reactions that often lead to life-threatening complications affecting various organs and the cardiovascular system. In a 'First in Human' study conducted earlier this year, Invizius demonstrated that H-Guard is not only safe but well-tolerated by patients. The research also yielded promising biomarker data that could indicate significant benefits for users. With this latest round of funding pushing the total capital raised by Invizius beyond £13 million, the company is well-positioned to continue its vital work and potentially revolutionize the treatment landscape for dialysis patients in the near future.
They've invested in Invizius
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Calculus Capital London  | 8 investment(s) investment(s) | more info | |||
2 |  Syensqo | 1 investment(s) investment(s) | more info | |||
3 |  University of Edinburgh’s Old College Capital | 1 investment(s) investment(s) | more info | |||
4 |  Scottish Enterprise Glasgow | 13 investment(s) investment(s) | 7 contacts contacts |
Click here for a full list of 6,312+ startup investors in the UK